

## SUPPLEMENTAL FILE 1


### *In Vitro* Efflux Ratios for Drugs

Drug		Overall	Caco-2	LLC-PK <sub>1</sub> -MDR1	MDCK-MDR1
Amprenavir	Count	20	7	3	10
	Geometric mean	13.83	3.25	11.70	40.12
	Minimum	1.02	1.02	4.4	15
	Maximum	240	6.4	42.8	240
Atazanavir	Count	12	11	0	1
	Geometric mean	7.35	6.92	-----	14.1
	Minimum	1.8	1.8	-----	14.1
	Maximum	40	40	-----	14.1
Atorvastatin	Count	11	4	2	5
	Geometric mean	6.31	3.83	6.14	9.53
	Minimum	1.28	1.28	5.9	4.46
	Maximum	38	12.8	6.4	38
Cetirizine	Count	12	5	0	7
	Geometric mean	6.60	2.43	-----	13.49
	Minimum	1.2	1.2	-----	5.47
	Maximum	111	4.7	-----	111
Cimetidine	Count	37	21	3	13
	Geometric mean	2.97	2.65	4.30	3.29
	Minimum	0.9	0.9	1.9	1
	Maximum	12.7	5.23	12.7	12.5
Colchicine	Count	15	9	2	4
	Geometric mean	11.81	16.82	4.07	9.07
	Minimum	1.8	5.6	1.8	3.46
	Maximum	44.2	40	9.2	44.2
Cyclosporine	Count	44	26	9	9
	Geometric mean	5.76	5.61	6.18	5.80
	Minimum	1.09	1.09	1.57	2.8
	Maximum	37.1	30	37.1	20
Dabigatran	Count	12	10	1	1
	Geometric mean	5.75	5.87	15	1.8
	Minimum	1.4	1.4	15	1.8
	Maximum	34.9	34.9	15	1.8
Dexamethasone	Count	14	5	5	4
	Geometric mean	3.19	1.81	3.01	6.99
	Minimum	0.968	0.968	1.74	1.9
	Maximum	12.4	3.2	7	12.4
Digoxin	Count	238	156	28	54
	Geometric mean	11.60	9.67	11.81	19.41
	Minimum	1.21	1.21	2.7	2

	Maximum	200	102	44.44	200
Domperidone	Count	8	6	1	1
	Geometric mean	13.83	11.48	18.7	31.2
	Minimum	2.8	2.8	18.7	31.2
	Maximum	45	45	18.7	31.2
Doxorubicin	Count	22	19	1	2
	Geometric mean	5.91	6.96	3.12	1.72
	Minimum	0.67	1.7	3.12	0.67
	Maximum	26.5	26.5	3.12	4.4
Erythromycin	Count	25	13	2	10
	Geometric mean	11.62	19.43	5.17	7.01
	Minimum	3.3	5	3.3	3.46
	Maximum	74.5	74.5	8.1	35
Etoposide	Count	21	13	1	7
	Geometric mean	9.26	10.99	4.1	7.56
	Minimum	2.8	4.8	4.1	2.8
	Maximum	31.1	24.9	4.1	31.1
Fexofenadine	Count	30	24	2	4
	Geometric mean	8.31	9.45	4.36	5.27
	Minimum	1	1	3.91	3.3
	Maximum	85	85	4.87	11.1
Imatinib	Count	13	3	3	7
	Geometric mean	9.27	2.95	5.75	18.58
	Minimum	1.3	1.3	2	7.2
	Maximum	150	4.5	14.2	150
Indinavir	Count	21	15	2	4
	Geometric mean	11.81	9.21	14.30	27.26
	Minimum	1.6	1.6	6.2	12
	Maximum	92.2	30	33	92.2
Irinotecan	Count	15	8	1	6
	Geometric mean	10.96	6.54	29.10	18.54
	Minimum	3.4	3.4	29.1	7.11
	Maximum	150	17	29.1	150
Loperamide	Count	31	19	2	10
	Geometric mean	6.75	2.93	5.81	34.02
	Minimum	0.8	0.8	2.62	7.77
	Maximum	237	27	12.9	237
Paclitaxel	Count	39	28	3	8
	Geometric mean	13.86	11.50	14.05	26.48
	Minimum	1.3	1.3	6.5	7.1
	Maximum	391	391	30.5	333.79
Prazosin	Count	27	12	3	12
	Geometric mean	4.54	3.79	5.87	5.11
	Minimum	1.19	1.19	3.97	2.4
	Maximum	21.1	13.7	12.1	21.1

Quinidine	Count	63	40	3	20
	Geometric mean	5.43	3.37	2.27	16.10
	Minimum	0.76	0.76	1.3	0.98
	Maximum	838	27.2	5.99	838
Rhodamine 123	Count	80	61	6	13
	Geometric mean	7.96	7.99	4.37	10.30
	Minimum	0.7	0.7	2.12	2.36
	Maximum	115	77.57	11.1	115
Risperidone	Count	15	9	2	4
	Geometric mean	2.24	2.16	3.29	2.01
	Minimum	0.6	0.6	2.7	1.2
	Maximum	5.73	5.73	4	5.3
Ritonavir	Count	22	10	6	6
	Geometric mean	18.69	12.23	21.65	32.70
	Minimum	1	2.1	7.7	1
	Maximum	380	142	56.5	380
Rivaroxaban	Count	18	10	1	7
	Geometric mean	8.18	5.91	5.46	13.76
	Minimum	2.82	2.82	5.46	9.78
	Maximum	22.8	11.53	5.46	22.8
Saquinavir	Count	49	32	3	14
	Geometric mean	21.25	16.57	18.01	38.86
	Minimum	1.56	1.56	5.3	2.8
	Maximum	585	585	149	261
Tacrolimus	Count	10	5	4	1
	Geometric mean	3.34	2.64	4.14	4.6
	Minimum	1.04	1.04	1.54	4.6
	Maximum	7.61	7.5	7.61	4.6
Talinolol	Count	38	34	3	1
	Geometric mean	9.52	10.06	6.32	5
	Minimum	1.05	1.05	2.71	5
	Maximum	39.6	39.6	19	5
Verapamil	Count	66	39	11	16
	Geometric mean	2.38	2.01	4.16	2.48
	Minimum	0.5	0.5	1.48	0.65
	Maximum	83	83	30.4	55
Vinblastine	Count	58	34	10	14
	Geometric mean	17.85	14.57	9.74	45.14
	Minimum	1.4	1.4	3.64	5.1
	Maximum	627	161	37.3	627
Vincristine	Count	11	7	2	2
	Geometric mean	6.99	9.78	2.37	6.35
	Minimum	2.01	4	2.01	6.31
	Maximum	39.7	39.7	2.8	6.4

Overall = ER values regardless of cell line



## References for ER Values

- Abe Y, Ota E, Harada H, Kanbe H, Kojima Y, Kanazawa T, Endo T, Murakami M, Kobayashi M. 2015. Species differences in the metabolism of ritobegron *in vitro* and assessment of potential interactions with transporters and cytochrome P450 enzymes. *Pharmazie*. 70(1):38-46.
- Achira M, Suzuki H, Ito K, Sugiyama Y. 1999. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. *AAPS PharmSci*. 1(4):E18.
- Adachi Y, Suzuki H, Sugiyama Y. 2001. Comparative studies on *in vitro* methods for evaluating *in vivo* function of MDR1 P-glycoprotein. *Pharm Res*. 18(12):1660-1668.
- Al-Ali AAA, Steffansen B, Holm R, Nielsen CU. 2018. Nonionic surfactants increase digoxin absorption in Caco-2 and MDCKII MDR1 cells: Impact on P-glycoprotein inhibition, barrier function, and repeated cellular exposure. *Int J Pharm*. 551(1-2):270-280.
- Al-Ali AAA, Quach JRC, Bundgaard C, Steffansen B, Holm R, Nielsen CU. 2018. Polysorbate 20 alters the oral bioavailability of etoposide in wild type and *mdr1a* deficient Sprague-Dawley rats. *Int J Pharm*. 543(1-2):352-360.
- Alani AW, Rao DA, Seidel R, Wang J, Jiao J, Kwon GS. 2010. The effect of novel surfactants and Solutol® HS 15 on paclitaxel aqueous solubility and permeability across a Caco-2 monolayer. *J Pharm Sci*. 99(8):3473-3485.
- Al-Saraf A, Holm R, Nielsen CU. 2016. Tween 20 increases intestinal transport of doxorubicin *in vitro* but not *in vivo*. *Int J Pharm*. 498(1-2):66-69.
- Alsenz J, Steffen H, Alex R. 1998. Active apical secretory efflux of the HIV protease inhibitors saquinavir and zidovudine in Caco-2 cell monolayers. *Pharm Res*. 15(3):423-428.
- Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, Wunderli-Allenspach H, Merkle HP, Langguth P. 1998. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. *J Pharm Sci*. 87(6):757-762.
- Agarwala S, Chen W, Cook TJ. 2004. Effect of chlorpyrifos on efflux transporter gene expression and function in Caco-2 cells. *Toxicol In Vitro*. 18(4):403-409.
- Ashiru-Oredope DA, Patel N, Forbes B, Patel R, Basit AW. 2011. The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers. *Int J Pharm*. 409(1-2):164-168.
- Augustijns PF, Bradshaw TP, Gan LS, Hendren RW, Thakker DR. 1993. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. *Biochem Biophys Res Commun*. 197(2):36-365.
- Aungst BJ, Nguyen NH, Bulgarelli JP, Oates-Lenz K. 2000. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. *Pharm Res*. 17(10):1175-1180.
- Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. 2006. Characterization of  $\beta$ -adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. *Fundam Clin Pharmacol*. 20(3):273-282.
- Bae JK, Kim YJ, Chae HS, Kim DY, Choi HS, Chin YW, Choi YH. 2017. Korean red ginseng extract enhances paclitaxel distribution to mammary tumors and its oral bioavailability by P-glycoprotein inhibition. *Xenobiotica*. 47(5):450-459.
- Balimane PV, Marino A, Chong S. 2008. P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate? *AAPS J*. 10(4):577-586.

- Balimane PV, Han YH, Chong S. 2006. Current industrial practices of assessing permeability and P-glycoprotein interaction. *AAPS J.* 8(1):E1-13.
- Balimane PV, Chong S. 2005. A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay. *Int J Pharm.* 301(1-2):80-88.
- Balimane PV, Patel K, Marino A, Chong S. 2004. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. *Eur J Pharm Biopharm.* 58(1):99-105.
- Baltes S, Fedrowitz M, Tortós CL, Potschka H, Löscher W. 2007. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. *J Pharmacol Exp Ther.* 320(1):331-343.
- Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Löscher W. 2007. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. *Neuropharmacology.* 52(2):333-346.
- Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S. 2009. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. *Eur J Pharm Sci.* 36(4-5):580-590.
- Bansal T, Awasthi A, Jaggi M, Khar RK, Talegaonkar S. 2008. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. *Life Sci.* 83(7-8):250-259.
- Barot M, Gokulgandhi MR, Pal D, Mitra AK. 2014. *In vitro* moxifloxacin drug interaction with chemotherapeutics: implications for retinoblastoma management. *Exp Eye Res.* 118:61-71.
- Béduneau A, Tempesta C, Fimbel S, Pellequer Y, Jannin V, Demarne F, Lamprecht A. 2014. A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure. *Eur J Pharm Biopharm.* 87(2):290-298.
- Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, *et al.* 2013. Variability in P-glycoprotein inhibitory potency (IC<sub>50</sub>) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. *Drug Metab Dispos.* 41(7):1347-1366.
- Berginc K, Trdan T, Trontelj J, Kristl A. 2010. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. *Biopharm Drug Dispos.* 31(8-9):495-505.
- Berginc K, Žakelj S, Kristl A. 2010. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. *Eur J Nutr.* 49(6):373-84.
- Bicker J, Fortuna A, Alves G, Soares-da-Silva P, Falcão A. 2017. Elucidation of the impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of catechol-O-methyltransferase Inhibitors. *Drug Metab Dispos.* 45(12):1282-1291.
- Bogman K, Zysset Y, Degen L, Hopfgartner G, Gutmann H, Alsenz J, Drewe J. 2005. P-glycoprotein and surfactants: effect on intestinal talinolol absorption. *Clin Pharmacol Ther.* 77(1):24-32.
- Bourdet DL, Thakker DR. 2006. Saturable absorptive transport of the hydrophilic organic cation ranitidine in Caco-2 cells: role of pH-dependent organic cation uptake system and P-glycoprotein. *Pharm Res.* 23(6):1165-1177.
- Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L. 2000. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. *J Clin Pharmacol.* 40(1):91-98.

- Brayden DJ, Griffin J. 2008. Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers. *Vet Res Commun.* 32(1):93-106.
- Bromberg L, Alakhov V. 2003. Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. *J Control Release.* 88(1):11-22.
- Brouwers J, Tack J, Lammert F, Augustijns P. 2006. Intraluminal drug and formulation behavior and integration in *in vitro* permeability estimation: a case study with amprenavir. *J Pharm Sci.* 95(2):372-383.
- Brown SM, Campbell SD, Crafford A, Regina KJ, Holtzman MJ, Kharasch ED. 2012. P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. *J Pharmacol Exp Ther.* 343(1):53-61.
- Brück S, Strohmeier J, Busch D, Drozdik M, Oswald S. 2017. Caco-2 cells - expression, regulation and function of drug transporters compared with human jejunal tissue. *Biopharm Drug Dispos.* 38(2):115-126.
- Cai Y, Xu C, Chen P, Hu J, Hu R, Huang M, Bi H. 2014. Development, validation, and application of a novel 7-day Caco-2 cell culture system. *J Pharmacol Toxicol Meth.* 70(2):175-181.
- Calitz C, Gouws C, Viljoen J, Steenekamp J, Wiesner L, Abay E, Hamman J. 2015. Herb-drug pharmacokinetic interactions: Transport and metabolism of indinavir in the presence of selected herbal products. *Molecules.* 20(12):22113-27.
- Caon T, Kratz JM, Kuminek G, Heller M, König RA, Micke GA, Koester LS, Simões CMO. 2015. Oral saquinavir mesylate solid dispersions: In vitro dissolution, Caco-2 cell model permeability and in vivo absorption studies. *Powder Technol.* 269:200-206.
- Cao Z, Li D, Liu L, Yang P. 2018. Effect of five novel 5-substituted tetrandrine derivatives on P-glycoprotein-mediated inhibition and transport in Caco-2 cells. *Oncol Lett.* 16(5):6808-6814.
- Carrara S, Reali V, Misiano P, Dondio G, Bigogno C. 2007. Evaluation of in vitro brain penetration: optimized PAMPA and MDCKII-MDR1 assay comparison. *Int J Pharm.* 345(1-2):125-133.
- Cavet ME, West M, Simmons NL. 1996. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. *Br J Pharmacol.* 118(6):1389-1396.
- Celius T, Garberg P, Lundgren B. 2004. Stable suppression of MDR1 gene expression and function by RNAi in Caco-2 cells. *Biochem Biophys Res Commun.* 324(1):365-71.
- Cerveny L, Ptackova Z, Durisova M, Staud F. 2018. Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats. *Reprod Toxicol.* 79:57-65.
- Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. 2006. Rapid identification of P-glycoprotein substrates and inhibitors. *Drug Metab Dispos.* 34(12):1976-1984.
- Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA. 2005. Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. *Drug Metab Dispos.* 33(4):537-546.
- Chen C, Hanson E, Watson JW, Lee JS. 2003. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. *Drug Metab Dispos.* 31(3):312-318.
- Chen Y, Li C, Yi Y, Du W, Jiang H, Zeng S, Zhou H. 2020. Organic cation transporter 1 and 3 contribute to the high accumulation of dehydrocorydaline in the heart. *Drug Metab Dispos.* 48(10):1074-1083.
- Chino Y, Hasegawa M, Fukasawa Y, Mano Y, Bando K, Miyata A, Nakai Y, Endo H, Yamaguchi

- Ji. 2017. *In vitro* evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor. *Xenobiotica*. 47(4):314-323.
- Cholkar K, Trinh HM, Vadlapudi AD, Wang Z, Pal D, Mitra AK. 2015. Interaction studies of resolvin E1 analog (RX-10045) with efflux transporters. *J Ocul Pharmacol Ther*. 31(4):248-255.
- Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. 2007. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. *J Pharmacol Exp Ther*. 321(2):673-683.
- Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G. 2004. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and *mdr1a*(-/-) mice *in vivo*. *Pharm Res*. 21(5):819-826.
- Collett A, Higgs NB, Sims E, Rowland M, Warhurst G. 1999. Modulation of the permeability of H<sub>2</sub> receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. *J Pharmacol Exp Ther*. 288(1):171-178.
- Collnot EM, Baldes C, Wempe MF, Hyatt J, Navarro L, Edgar KJ, Schaefer UF, Lehr CM. 2006. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. *J Control Release*. 111(1-2):35-40.
- Cousein E, Barthélémy C, Poullain S, Simon N, Lestavel S, Willame V, Joiris E, Danel C, Clavey V, Brossard D, *et al.* 2007. P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an *in vitro* Caco-2/TC7 model and an *in vivo* model. *Prog Neuropsychopharmacol Biol Psychiatry*. 31(4):878-86.
- Crivori P, Reinach B, Pezzetta D, Poggese I. 2006. Computational models for identifying potential P-glycoprotein substrates and inhibitors. *Mol Pharm*. 3(1):33-44.
- Crowe A, Wright C. 2012. The impact of P-glycoprotein mediated efflux on absorption of 11 sedating and less-sedating antihistamines using Caco-2 monolayers. *Xenobiotica*. 42(6):538-549.
- Crowe A, Tan AM. 2012. Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. *Toxicol Appl Pharmacol*. 260(3):294-302.
- Crowe A, Wong P. 2004. pH dependent uptake of loperamide across the gastrointestinal tract: an *in vitro* study. *Drug Dev Ind Pharm*. 30(5):449-459.
- Crowe A, Wong P. 2003. Potential roles of P-gp and calcium channels in loperamide and diphenoxylate transport. *Toxicol Appl Pharmacol*. 193(1):127-137.
- Crowe A. 2002. The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel. *Eur J Pharmacol*. 440(1):7-16.
- Crowe A, Lemaire M. 1998. *In vitro* and *in situ* absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. *Pharm Res*. 15(11):1666-1672.
- Dahan A, Amidon GL. 2009. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. *Mol Pharm*. 6(1):19-28.
- Dahan A, Sabit H, Amidon GL. 2009. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. *Drug Metab Dispos*. 37(10):2028-2036.
- Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. 2003. Distribution of STI-571 to the brain



- is limited by P-glycoprotein-mediated efflux. *J Pharmacol Exp Ther.* 304(3):1085-1092.
- Darvari R, Boroujerdi M. 2004. Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin--a comparison with tamoxifen. *J Pharm Pharmacol.* 56(8):985-991.
- de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. 2007. Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. *J Pharm Sci.* 96(10):2808-2817.
- Dechongy P, Limpisood S, Boonnak N, Mangmool S, Takeda-Morishita M, Kulsirirat T, Rukthong P, Sathirakul K. 2020. The intestinal efflux transporter inhibition activity of xanthenes from mangosteen pericarp: An in silico, in vitro and ex vivo approach. *Molecules.* 25(24):5877.
- Deferme S, Tack J, Lammert F, Augustijns P. 2003. P-glycoprotein attenuating effect of human intestinal fluid. *Pharm Res.* 20(6):900-903.
- Deferme S, Kamuhabwa A, Nshimo C, de Witte P, Augustijns P. 2003. Screening of Tanzanian plant extracts for their potential inhibitory effect on P-glycoprotein mediated efflux. *Phytother Res.* 17(5):459-464.
- Deferme S, Mols R, Van Driessche W, Augustijns P. 2002. Apricot extract inhibits the P-gp-mediated efflux of talinolol. *J Pharm Sci.* 91(12):2539-2548.
- Deferme S, Van Gelder J, Augustijns P. 2002. Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an in-vitro screening. *J Pharm Pharmacol.* 54(9):1213-1219.
- Dey S, Gunda S, Mitra AK. 2004. Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. *J Pharmacol Exp Ther.* 311(1):246-255.
- Dickens D, Owen A, Alfirevic A, Pirmohamed M. 2013. ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein. *Pharmacogenet Genomics.* 23(6):314-23.
- Dickens D, Owen A, Alfirevic A, Pirmohamed M. 2009. Determination of the inhibitory potencies of P-glycoprotein inhibitors by transcellular permeability of Caco-2 cells. *pA<sub>2</sub> Online.* 7(4):abstract 092P.
- Dilger K, Schwab M, Fromm MF. 2004. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. *Inflamm Bowel Dis.* 10(5):578-583.
- Djuv A, Nilsen OG. 2008. Caco-2 cell methodology and inhibition of the P-glycoprotein transport of digoxin by *Aloe vera* juice. *Phytother Res.* 22(12):1623-1628.
- dos Reis Júnior MA, de Faria ACM, da Silva Velozo E, Dalla Costa T, de Andrade FP, de Castro WV. 2015. Determination of fexofenadine in Hank's balanced salt solution by high-performance liquid chromatography with ultraviolet detection: Application to Caco-2 cell permeability studies. *Biomed Chromatography.* 29(4):537-544.
- Eagling VA, Profit L, Back DJ. 1999. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. *Br J Clin Pharmacol.* 48(4):543-552.
- Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, Dörje F, Mürdter TE, Ackermann A, Dormann H, *et al.* 2007. Role of p-glycoprotein inhibition for drug interactions: evidence from *in vitro* and pharmacoepidemiological studies. *Clin Pharmacokinet.* 46(12):1039-1049.
- Ebner T, Ishiguro N, Taub ME. 2015. The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting-proposal of a four component transporter cocktail. *J Pharm Sci.* 104(9):3220-3228.

- El Ela AA, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. . 2004. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. *J Pharm Pharmacol* 56(8):967-975.
- Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. 2013. Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol. *Pharm Res.* 30(12):3029-3044.
- Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, Surry DD. 2011. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. *Drug Metab Dispos.* 39(2):275-282.
- Elsby R, Surry DD, Smith VN, Gray AJ. 2008. Validation and application of Caco-2 assays for the *in vitro* evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. *Xenobiotica.* 38(7-8):1140-1164.
- Eriksson UG, Dorani H, Karlsson J, Fritsch H, Hoffmann KJ, Olsson L, Sarich TC, Wall U, Schützer KM. 2006. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. *Drug Metab Dispos.* 34(5):775-782.
- Faassen F, Vogel G, Spanings H, Vromans H. 2003. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. *Int J Pharm.* 263(1-2):113-122.
- Faessel HM, Burstein AH, Troutman MD, Willavize SA, Rohrbacher KD, Clark DJ. 2008. Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. *Eur J Clin Pharmacol.* 64(11):1101-1109.
- Fan J, Maeng HJ, Du Y, Kwan D, Pang KS. 2011. Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells. *Eur J Pharm Sci.* 42(1-2):19-29.
- Fan J, Liu S, Du Y, Morrison J, Shipman R, Pang KS. 2009. Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and vitamin D analogs, in the Caco-2 cell monolayer. *J Pharmacol Exp Ther.* 330(2):389-402.
- Fan J, Maeng HJ, Du Y, Kwan D, Pang KS. 2011. Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells. *Eur J Pharm Sci.* 42(1-2):19-29.
- Fan Y, Rodriguez-Proteau R. 2008. Ketoconazole and the modulation of multidrug resistance-mediated transport in Caco-2 and MDCKII-MDR1 drug transport models. *Xenobiotica.* 38(2):107-129.
- Feng B, Doran AC, Di L, West MA, Osgood SM, Mancuso JY, Shaffer CL, Tremaine L, Liras J. 2018. Prediction of human brain penetration of P-glycoprotein and breast cancer resistance protein substrates using *in vitro* transporter studies and animal models. *J Pharm Sci.* 107(8):2225-2235.
- Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM. 2008. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. *Drug Metab Dispos.* 36(2):268-275.
- Fenyvesi F, Kiss T, Fenyvesi E, Szenté L, Veszélka S, Deli MA, Váradi J, Fehér P, Ujhelyi Z, Tótsaki A, Vecsernyés M, Bácskay I. 2011. Randomly methylated  $\beta$ -cyclodextrin derivatives enhance taxol permeability through human intestinal epithelial Caco-2 cell monolayer. *J Pharm Sci.* 100(11):4734-4744.
- Föger F, Kafedjiiski K, Hoyer H, Loretz B, Bernkop-Schnürch A. 2007. Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. *J Drug Target.* 15(2):132-139.

- Francis MF, Cristea M, Yang Y, Winnik FM. 2005. Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin A across Caco-2 cells. *Pharm Res.* 22(2):209-219.
- Fuchs H, Kishimoto W, Gansser D, Tanswell P, Ishiguro N. 2014. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats. *Drug Metab Dispos.* 42(10):1761-1765.
- Gallagher E, Minn I, Chambers JE, Searson PC. 2016. In vitro characterization of pralidoxime transport and acetylcholinesterase reactivation across MDCK cells and stem cell-derived human brain microvascular endothelial cells (BC1-hBMECs). *Fluids Barriers CNS.* 13(1):10.
- Gartzke D, Delzer J, Laplanch L, Uchida Y, Tachikawa M, Terasaki T, Sydor J, Fricker G. 2015. Genomic knockout of endogenous canine P-glycoprotein in wild-type, human P-glycoprotein and human BCRP transfected MDCKII cell lines by zinc finger nucleases. *Pharm Res.* 32(6):2060-2071.
- Gartzke D, Fricker G. 2014. Establishment of optimized MDCK cell lines for reliable efflux transport studies. *J Pharm Sci.* 103(4):1298-1304.
- Gertz M, Harrison A, Houston JB, Galetin A. 2010. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. *Drug Metab Dispos.* 38(7):1147-1158.
- Gnoth MJ, Buethorn U, Muenster U, Schwarz T, Sandmann S. 2011. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. *J Pharmacol Exp Ther.* 338(1):372-380.
- Gnoth MJ, Sandmann S, Engel K, Radtke M. 2010. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. *Drug Metab Dispos.* 38(8):1341-1346.
- Gong IY, Mansell SE, Kim RB. 2013. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. *Basic Clin Pharmacol Toxicol.* 112(3):164-170.
- Grammen C, Baes M, Haenen S, Verguts J, Augustyns K, Zydowsky T, La Colla P, Augustijns P, Brouwers J. 2014. Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits. *Mol Pharm.* 11(12):4405-4414.
- Griffin J, Fletcher N, Clemence R, Blanchflower S, Brayden DJ. 2005. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. *J Vet Pharmacol Ther.* 28(3):257-265.
- Guan Y, Huang J, Zuo L, Xu J, Si L, Qiu J, Li G. 2011. Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism. *Arch Pharm Res.* 34(10):1719-1728.
- Gundogdu E, Gonzalez Alvarez I, Bermejo Sanz M, Karasulu E. 2011. Assessment of fexofenadine hydrochloride permeability and dissolution with an anionic surfactant using Caco-2 cells. *Pharmazie.* 66(10):747-753.
- Guo A, Marinaro W, Hu P, Sinko PJ. 2002. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). *Drug Metab Dispos.* 30(4):457-463.
- Han Y, Tan TM, Lim LY. 2006. Effects of capsaicin on P-gp function and expression in Caco-2 cells. *Biochem Pharmacol.* 71(12):1727-1734.
- Han Y, Chin Tan TM, Lim LY. 2008. In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. *Toxicol Appl Pharmacol.* 230(3):283-289.

- Han YH, Busler D, Hong Y, Tian Y, Chen C, Rodrigues AD. 2010. Transporter studies with the 3-*O*-sulfate conjugate of 17 $\alpha$ -ethinylestradiol: assessment of human liver drug transporters. *Drug Metab Dispos.* 38(7):1072-82.
- Hansen TS, Nilsen OG. 2009. Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells. *Phytother Res.* 23(1):86-91.
- Hariharan S, Gunda S, Mishra GP, Pal D, Mitra AK. 2009. Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. *Pharm Res.* 26(5):1270-1282.
- Haslam IS, Jones K, Coleman T, Simmons NL. 2008. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). *Biochem Pharmacol.* 76(7):850-861.
- Hassan HE, Myers AL, Coop A, Eddington ND. 2009. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: *in vitro* and *in vivo* evaluation. *J Pharm Sci.* 98(12):4928-4940.
- Hassan HE, Myers AL, Lee IJ, Coop A, Eddington ND. 2007. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. *J Pharm Sci.* 96(9):2494-2506.
- Havenga K, Abay E, Wiesner L, Viljoen A, Steyn D, Hamman J. 2018. The *in vitro* and *in vivo* effects of *Hypoxis hemerocallidea* on indinavir pharmacokinetics: Modulation of efflux. *Planta Med.* 84(12-13):895-901.
- Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, *et al.* 2008. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. *Eur J Pharm Sci.* 35(5):383-396.
- Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL. 2006. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. *Eur J Pharm Sci.* 29(1):70-81.
- He Y, Wei Z, Xie Y, Yi X, Zeng Y, Li Y, Liu C. 2020. Potential synergic mechanism of Wutou-Gancao herb-pair by inhibiting efflux transporter P-glycoprotein. *J Pharm Anal.* 10(2):178-186.
- He Y, Liu Y, Zeng S. 2010. Stereoselective and multiple carrier-mediated transport of cetirizine across Caco-2 cell monolayers with potential drug interaction. *Chirality.* 22(7):684-692.
- Hellinger E, Veszelka S, Tóth AE, Walter F, Kittel A, Bakk ML, Tihanyi K, Háda V, Nakagawa S, Duy TD, *et al.* 2012. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. *Eur J Pharm Biopharm.* 82(2):340-351.
- Hellinger É, Bakk ML, Pócza P, Tihanyi K, Vastag M. 2010. Drug penetration model of vinblastine-treated Caco-2 cultures. *Eur J Pharm Sci.* 41(1):96-106.
- Hilgendorf C, Spahn-Langguth H, Rhedin M, Regårdh CG, Löwenadler B, Langguth P. 2005. Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport. *Mol Pharm.* 2(1):64-73.
- Hilgendorf C, Spahn-Langguth H, Regårdh CG, Lipka E, Amidon GL, Langguth P. 2000. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: Permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. *J Pharm Sci.* 89(1):63-75.
- Himanshu R, Jakir P, Pradnya H, Suneel P, Rahul S. 2013. The impact of permeability enhancers on assessment for monolayer of colon adenocarcinoma cell line (Caco-2) used in *in vitro* permeability assay. *J Drug Deliv Ther.* 3(3):20-29.

- Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T. 2004. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. *Pharm Res.* 21(9):1686-1691.
- Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH. 2000. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. *J Pharmacol Exp Ther.* 292(1):310-318.
- Hodin S, Basset T, Jacqueroux E, Delezay O, Clotagatide A, Perek N, Mismetti P, Delavenne X. 2018. In vitro comparison of the role of P-glycoprotein and breast cancer resistance protein on direct oral anticoagulants disposition. *Eur J Drug Metab Pharmacokinet.* 43(2):183-191.
- Hoffmann G, Funk C, Fowler S, Otteneder MB, Breidenbach A, Rayner CR, Chu T, Prinssen EP. 2009. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. *Antimicrob Agents Chemother.* 53(11):4753-4761.
- Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. 2004. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. *Br J Pharmacol.* 143(7):856-864.
- Horie K, Tang F, Borchardt RT. 2003. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. *Pharm Res.* 20(2):161-168.
- Hou J, Sun E, Sun C, Wang J, Yang L, Jia XB, Zhang ZH. 2016. Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus®-Solutol® HS15 binary mixed micelles system. *Int J Pharm.* 512(1):186-193.
- Hu T, To KK, Wang L, Zhang L, Lu L, Shen J, Chan RL, Li M, Yeung JH, Cho CH. 2014. Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of *Salvia miltiorrhiza*. *Phytomedicine.* 21(11):1264-1272.
- Hu S, Franke RM, Filipinski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A. 2008. Interaction of imatinib with human organic ion carriers. *Clin Cancer Res.* 14(10):3141-3148.
- Hu Z, Zhou Z, Hu Y, Wu J, Li Y, Huang W. 2015. HZ08 reverse P-glycoprotein mediated multidrug resistance *in vitro* and *in vivo*. *PLoS One.* 10(2):e0116886.
- Huang K, Hu J, Li X, Li Y. 2012. Role of P-glycoprotein in intestinal absorption of FB2, a promising Abl/Src dual tyrosine kinase inhibitor. *Drug Metab Pharmacokinet.* 27(5):486-494.
- Huang L, Berry L, Ganga S, Janosky B, Chen A, Roberts J, Colletti AE, Lin MH. 2010. Relationship between passive permeability, efflux, and predictability of clearance from *in vitro* metabolic intrinsic clearance. *Drug Metab Dispos.* 38(2):223-231.
- Huang L, Wang Y, Grimm S. 2006. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. *Drug Metab Dispos.* 34(5):738-742.
- Huang Y, Zhao J, Jian W, Wang G. 2018. Effects of verapamil on the pharmacokinetics of dihydromyricetin in rats and its potential mechanism. *Xenobiotica.* 48(8):839-844.
- Hugger ED, Audus KL, Borchardt RT. 2002. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. *J Pharm Sci.* 91(9):1980-1990.
- Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. 2002. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity *in vitro*. *J Pharm Sci.* 91(9):1991-2002.
- Hughes J, Crowe A. 2010. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. *J Pharmacol Sci.* 113(4):315-324.

- Hunter J, Hirst BH, Simmons NL. 1993. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. *Pharm Res.* 10(5):743-749.
- Huo X, Liu Q, Wang C, Meng Q, Sun H, Peng J, Ma X, Liu K. 2013. Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin. *Eur J Pharm Sci.* 50(3-4):420-428.
- Hutter V, Chau, DYS, Hilgendorf C, Brown A, Cooper A, Zann V, Pritchard DI, Bosquillon C. 2014. Digoxin net secretory transport in bronchial epithelial cell layers is not exclusively mediated by P-glycoprotein/MDR1. *Eur J Pharm Biopharm.* 86(1):74-86.
- Hye HY, Lee M, Min WL, Sun YL, Shin J, Kim DH. 2007. Effects of *Schisandra* lignans on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. *Planta Medica.* 73(5):444-450.
- Ingels F, Beck B, Oth M, Augustijns P. 2004. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. *Int J Pharm.* 274(1-2):221-232.
- Ingels F, Deferme S, Destexhe E, Oth M, Van den Mooter G, Augustijns P. 2002. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. *Int J Pharm.* 232(1-2):183-192.
- Inoue T, Osada K, Tagawa M, Ogawa Y, Haga T, Sogame Y, Hashizume T, Watanabe T, Taguchi A, Katsumata T, *et al.* 2012. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein. *Prog Neuropsychopharmacol Biol Psychiatry.* 39(1):156-162.
- Ishiguro N, Kishimoto W, Volz A, Ludwig-Schwellinger E, Ebner T, Schaefer O. 2014. Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers. *Drug Metab Dispos.* 42(2):250-256.
- Ishiguro N, Shimizu H, Kishimoto W, Ebner T, Schaefer O. 2013. Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. *Drug Metab Dispos.* 41(1):149-158.
- Iwai M, Minematsu T, Li Q, Iwatsubo T, Usui T. 2011. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK<sub>1</sub> cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein. *Drug Metab Dispos.* 39(12):2314-2320.
- Iwanaga K, Hayashi M, Hamahata Y, Miyazaki M, Shibano M, Taniguchi M, Baba K, Kakemi M. 2010. Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein. *Drug Metab Dispos.* 38(8):1286-1294.
- Jacqueroix E, Mercier C, Margelidon-Cozzolino V, Hodin S, Bertoletti L, Delavenne X. 2020. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants. *Fundam Clin Pharmacol.* 34(1):109-119.
- Jacqueroix E, Hodin S, Saib S, He Z, Bin V, Delézay O, Delavenne X. 2020. Value of quantifying ABC transporters by mass spectrometry and impact on *in vitro*-to-*in vivo* prediction of transporter-mediated drug-drug interactions of rivaroxaban. *Eur J Pharm Biopharm.* 148:27-37.
- Jin H, Zhu Y, Wang C, Meng Q, Wu J, Sun P, Ma X, Sun H, Huo X, Liu K, Tan A. 2020. Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. *Biomed Pharmacother.* 125:110032.
- Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, Potter B, Sousa JC, Olmeda R, Li Q, *et al.* 2014. Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays

- for anti-malarial drug screening and drug investigations. *J Pharmacol Toxicol Methods*. 70(2):188-194.
- Jing YR, Zhou W, Li WL, Zhao LX, Wang YF. 2014. The synthesis of novel taxoids for oral administration. *Bioorg Med Chem*. 22(1):194-203.
- Kakumoto M, Takara K, Sakaeda T, Tanigawara Y, Kita T, Okumura K. 2002. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. *Biol Pharm Bull*. 25(12):1604-1607.
- Kamiya Y, Omura A, Hayasaka R, Saito R, Sano I, Handa K, Ohori J, Kitajima M, Shono F, Funatsu K, Yamazaki H. 2021. Prediction of permeability across intestinal cell monolayers for 219 disparate chemicals using *in vitro* experimental coefficients in a pH gradient system and *in silico* analyses by trivariate linear regressions and machine learning. *Biochem Pharmacol*. 192:114749.
- Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O. 2010. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. *Life Sci*. 86(1-2):52-58.
- Kamiyama E, Sugiyama D, Nakai D, Miura S, Okazaki O. 2009. Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells. *Drug Metab Dispos*. 37(9):1956-1962.
- Kanaan M, Daali Y, Dayer P, Desmeules J. 2008. Lack of interaction of the NMDA receptor antagonists dextromethorphan and dextrorphan with P-glycoprotein. *Curr Drug Metab*. 9(2):144-151.
- Kang JW, Cho HJ, Lee HJ, Jin HE, Maeng HJ. 2019. Polyethylene glycol-decorated doxorubicin/carboxymethyl chitosan/gold nanocomplex for reducing drug efflux in cancer cells and extending circulation in blood stream. *Int J Biol Macromol*. 125:61-71.
- Karlgren M, Simoff I, Backlund M, Wegler C, Keiser M, Handin N, Müller J, Lundquist P, Jareborg AC, Oswald S, Artursson P. 2017. A CRISPR-Cas9 generated MDCK cell line expressing human MDR1 without endogenous canine MDR1 (*cABCB1*): An improved tool for drug efflux studies. *J Pharm Sci*. 106(9):2909-2913.
- Katneni K, Pham T, Saunders J, Chen G, Patil R, White KL, Abila N, Chiu FCK, Shackelford DM, Charman SA. 2018. Using human plasma as an assay medium in Caco-2 studies improves mass balance for lipophilic compounds. *Pharm Res*. 35(11):210.
- Karyekar CS, Eddington ND, Garimella TS, Gubbins PO, Dowling TC. 2003. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model. *Pharmacotherapy*. 23(4):436-442.
- Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T. 2006. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. *J Pharm Sci*. 95(12):2673-2683.
- Kawaguchi H, Akazawa Y, Watanabe Y, Takakura Y. 2005. Permeability modulation of human intestinal Caco-2 cell monolayers by interferons. *Eur J Pharm Biopharm*. 59(1):45-50.
- Keogh JP, Kunta JR. 2006. Development, validation and utility of an *in vitro* technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. *Eur J Pharm Sci*. 27(5):543-554.
- Kigen G, Edwards G. Enhancement of saquinavir absorption and accumulation through the formation of solid drug 2018. nanoparticles. *BMC Pharmacol Toxicol*. 19(1):79.
- Kim JE, Cho HJ, Kim JS, Shim CK, Chung SJ, Oak MH, Yoon IS, Kim DD. 2013. The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of

- doxorubicin. *Xenobiotica*. 43(7):579-91.
- Kis O, Walmsley SL, Bendayan R. 2014. In vitro and in situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents. *Pharm Res*. 31(9):2404-2419.
- Kis O, Zastre JA, Hoque MT, Walmsley SL, Bendayan R. 2013. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. *Pharm Res*. 30(4):1050-1064.
- Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, Ebner T, Maeda K, Sugiyama Y. 2016. Usefulness of a model-based approach for estimating *in vitro* P-glycoprotein inhibition potency in a transcellular transport assay. *J Pharm Sci*. 105(2):891-896.
- Kishimoto W, Ishiguro N, Saito A, Ebner T, Härtter S, Igarashi T. 2010. Characterization of drug transporters involved in the disposition of dabigatran etexilate and its active form, dabigatran. *Drug Metab Rev*. 42(suppl 1):293.
- Kivistö KT, Zukunft J, Hofmann U, Niemi M, Rekersbrink S, Schneider S, Luippold G, Schwab M, Eichelbaum M, Fromm MF. 2004. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and *mdr1a/b* knock-out mice. *Naunyn Schmiedebergs Arch Pharmacol*. 370(2):124-130.
- Kobayashi K, Abe Y, Kawai A, Furihata T, Endo T, Takeda H. 2020. Pharmacokinetic drug interactions of an orally available TRH analog (rovatirelin) with a CYP3A4/5 and P-glycoprotein inhibitor (itraconazole). *J Clin Pharmacol*. 60(10):1314-1323.
- Koljonen M, Hakala KS, Ahtola-Sättilä T, Laitinen L, Kostiaainen R, Kotiaho T, Kaukonen AM, Hirvonen J. 2006. Evaluation of cocktail approach to standardise Caco-2 permeability experiments. *Eur J Pharm Biopharm*. 64(3):379-387.
- Korjamo T, Kemiläinen H, Heikkinen AT, Mönkkönen J. 2007. Decrease in intracellular concentration causes the shift in  $K_m$  value of efflux pump substrates. *Drug Metab Dispos*. 35(9):1574-1579.
- Korjamo T, Mönkkönen J, Uusitalo J, Turpeinen M, Pelkonen O, Honkakoski P. 2006. Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. *Pharm Res*. 23(9):1991-2001.
- Korjamo T, Honkakoski P, Toppinen MR, Niva S, Reinisalo M, Palmgrén JJ, Mönkkönen J. 2005. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. *Eur J Pharm Sci*. 26(3-4):266-279.
- Korzekwa KR, Nagar S, Tucker J, Weiskircher EA, Bhoopathy S, Hidalgo IJ. 2012. Models to predict unbound intracellular drug concentrations in the presence of transporters. *Drug Metab Dispos*. 40(5):865-876.
- Kratz JM, Teixeira MR, Koester LS, Simões CM. 2011. An HPLC-UV method for the measurement of permeability of marker drugs in the Caco-2 cell assay. *Braz J Med Biol Res*. 44(6):531-537.
- Küblbeck J, Hakkarainen JJ, Petsalo A, Vellonen KS, Tolonen A, Reponen P, Forsberg MM, Honkakoski P. 2016. Genetically modified Caco-2 cells with improved cytochrome P450 metabolic capacity. *J Pharm Sci*. 105(2):941-949.
- Kumar L, Meena CL, Pawar YB, Wahlang B, Tikoo K, Jain R, Bansal AK. 2013. Effect of counterions on physicochemical properties of prazosin salts. *AAPS PharmSciTech*. 14(1):141-150.
- Kusuhara H, Miura M, Yasui-Furukori N, Yoshida K, Akamine Y, Yokochi M, Fukizawa S, Ikejiri K, Kanamitsu K, Uno T, *et al*. 2013. Effect of coadministration of single and multiple doses



- of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects. *Drug Metab Dispos.* 41(1):206-213.
- Kuteykin-Teplyakov K, Luna-Tortós C, Ambroziak K, Löscher W. 2010. Differences in the expression of endogenous efflux transporters in *MDR1*-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. *Br J Pharmacol.* 160(6):1453-1463.
- Kwatra D, Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK. 2010. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. *Int J Pharm.* 395(1-2):114-121.
- Lamoureux F, Picard N, Boussera B, Sauvage FL, Marquet P. 2012. Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. *Fundam Clin Pharmacol.* 26(4):463-472.
- Lazorova L, Hubatsch I, Ekegren JK, Gising J, Nakai D, Zaki NM, Bergström CA, Norinder U, Larhed M, Artursson P. 2011. Structural features determining the intestinal epithelial permeability and efflux of novel HIV-1 protease inhibitors. *J Pharm Sci.* 100(9):3763-3772.
- Lee SD, Osei-Twum JA, Wasan KM. 2013. Dose-dependent targeted suppression of P-glycoprotein expression and function in Caco-2 cells. *Mol Pharm.* 10(6):2323-2330.
- Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE. 2000. Influence of passive permeability on apparent P-glycoprotein kinetics. *Pharm Res.* 17(12):1456-1460.
- Lentz KA, Hayashi J, Lucisano LJ, Polli JE. 2000. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. *Int J Pharm.* 200(1):41-51.
- Lepist EI, Phan TK, Roy A, Tong L, MacLennan K, Murray B, Ray AS. 2012. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, *in vitro*. *Antimicrob Agents Chemother.* 56(10):5409-5413.
- Li J, Wang Y, Hidalgo IJ. 2013. Kinetic analysis of human and canine P-glycoprotein-mediated drug transport in MDR1-MDCK cell model: approaches to reduce false-negative substrate classification. *J Pharm Sci.* 102(9):3436-3446.
- Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, Hidalgo IJ. 2011. Use of transporter knockdown Caco-2 cells to investigate the *in vitro* efflux of statin drugs. *Drug Metab Dispos.* 39(7):1196-1202.
- Li L, Fu Q, Xia M, Xin L, Shen H, Li G, Ji G, Meng Q, Xie Y. 2018. Inhibition of P-glycoprotein mediated efflux in Caco-2 cells by phytic acid. *J Agric Food Chem.* 66(4):988-998.
- Li N, Wang D, Ge G, Wang X, Liu Y, Yang L. 2014. Ginsenoside metabolites inhibit P-glycoprotein *in vitro* and *in situ* using three absorption models. *Planta Med.* 80(4):290-296. PMID: 24493631.
- Li W, Li X, Gao Y, Zhou Y, Ma S, Zhao Y, Li J, Liu Y, Wang X, Yin D. 2014. Inhibition mechanism of P-glycoprotein mediated efflux by mPEG-PLA and influence of PLA chain length on P-glycoprotein inhibition activity. *Mol Pharm.* 11(1):71-80.
- Liu X, Sun H, Zhang Y, Sun Y, Wang W, Xu L, Liu W. 2021. Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport *in vivo* and *in vitro*: A safety attention to antipsychotic polypharmacy with clozapine and risperidone. *Toxicol Appl Pharmacol.* 422:115560.
- Li X, Hu J, Wang B, Sheng L, Liu Z, Yang S, Li Y. 2014. Inhibitory effects of herbal constituents on P-glycoprotein *in vitro* and *in vivo*: herb-drug interactions mediated via P-gp. *Toxicol Appl Pharmacol.* 275(2):163-175.
- Li YH, Bi HC, Huang L, Jin J, Zhong GP, Zhou XN, Huang M. 2014. Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2

- cell monolayer models. *Acta Pharmacol Sinica*. 35(2):283-291.
- Liang E, Chessic K, Yazdanian M. 2000. Evaluation of an accelerated Caco-2 cell permeability model. *J Pharm Sci*. 89(3):336-345.
- Liang S, Deng F, Xing H, Wen H, Shi X, Martey ON, Koomson E, He X. 2014. P-glycoprotein- and organic anion-transporting polypeptide-mediated transport of periplocin may lead to drug-herb/drug-drug interactions. *Drug Des Devel Ther*. 8:475-483.
- Liang Y, Zhou Y, Zhang J, Liu Y, Guan T, Wang Y, Xing L, Rao T, Zhou L, Hao K, *et al*. 2013. *In vitro* to *in vivo* evidence of the inhibitor characteristics of *Schisandra* lignans toward P-glycoprotein. *Phytomedicine*. 20(11):1030-1038.
- Liang Y, Zhou Y, Zhang J, Rao T, Zhou L, Xing R, Wang Q, Fu H, Hao K, Xie L, Wang G. 2014. Pharmacokinetic compatibility of ginsenosides and *Schisandra* lignans in *Shengmai-san*: from the perspective of p-glycoprotein. *PLoS One*. 9(6):e98717.
- Lim SL, Lim LY. 2006. Effects of citrus fruit juices on cytotoxicity and drug transport pathways of Caco-2 cell monolayers. *Int J Pharm*. 307(1):42-50.
- Lin X, Skolnik S, Chen X, Wang J. 2011. Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. *Drug Metab Dispos*. 39(2):265-274.
- Lind ML, Jacobsen J, Holm R, Müllertz A. 2007. Development of simulated intestinal fluids containing nutrients as transport media in the Caco-2 cell culture model: assessment of cell viability, monolayer integrity and transport of a poorly aqueous soluble drug and a substrate of efflux mechanisms. *Eur J Pharm Sci*. 32(4-5):261-270.
- Liu H, Yu N, Lu S, Ito S, Zhang X, Prasad B, He E, Lu X, Li Y, Wang F, *et al*. 2015. Solute carrier family of the organic anion-transporting polypeptides 1A2- Madin-Darby canine kidney II: A promising *in vitro* system to understand the role of organic anion-transporting polypeptide 1A2 in blood-brain barrier drug penetration. *Drug Metab Dispos*. 43(7):1008-1018.
- Liu L, Fan L, Peng X, Hu D, Zhou H. 2010. MDR1 C2005T polymorphism changes substrate specificity. *Cancer Chemother Pharmacol*. 66(3):617-623.
- Liu Q, Sun H, Chen XG, Li Y, Chen H, You F, Bao XQ, Zhang D, Shi JG. 2015. EM-E-11-4 increases paclitaxel uptake by inhibiting P-glycoprotein-mediated transport in Caco-2 cells. *J Asian Nat Prod Res*. 17(6):649-655.
- Liu Q, Wang C, Meng Q, Huo X, Sun H, Peng J, Ma X, Sun P, Liu K. 2014. MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate. *Pharm Res*. 31(5):1120-1132.
- Liu X, Sun H, Zhang Y, Sun Y, Wang W, Xu L, Liu W. 2021. Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport *in vivo* and *in vitro*: A safety attention to antipsychotic polypharmacy with clozapine and risperidone. *Toxicol Appl Pharmacol*. 422:115560.
- Lowes S, Cavet ME, Simmons NL. 2003. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. *Eur J Pharmacol*. 458():49-56.
- Lu J, Zhang Y, Sun M, Liu M, Wang X. 2017. Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein. *Phytomedicine*. 26:1-10.
- Luna-Tortós C, Fedrowitz M, Löscher W. 2008. Several major antiepileptic drugs are substrates for human P-glycoprotein. *Neuropharmacology*. 55(8):1364-1375.
- Luo S, Wang Z, Patel M, Khurana V, Zhu X, Pal D, Mitra AK. 2011. Targeting SVCT for enhanced drug absorption: synthesis and *in vitro* evaluation of a novel vitamin C conjugated prodrug of

- saquinavir. *Int J Pharm.* 414(1-2):77-85.
- Ma B, Chai S, Li N, To KK, Kan WL, Yang D, Lin G. Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic  $\alpha$ -aminoxy peptidomimetic. *Int J Pharm.* 2012. 424(1-2):33-39.
- Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. 2002. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. *J Pharmacol Exp Ther.* 303(3):1029-37.
- Maharao NV, Joshi AA, Gerk PM. 2017. Inhibition of glucuronidation and oxidative metabolism of buprenorphine using GRAS compounds or dietary constituents/supplements: *in vitro* proof of concept. *Biopharm Drug Dispos.* 38(2):139-154.
- Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. 1998. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. *Pharm Res.* 15(8):1160-1167.
- Margelidon-Cozzolino V, Hodin S, Jacqueroux E, Delézy O, Bertoletti L, Delavenne X. 2018. In vitro assessment of pharmacokinetic drug-drug interactions of direct oral anticoagulants: Type 5-phosphodiesterase inhibitors are inhibitors of rivaroxaban and apixaban efflux by P-glycoprotein. *J Pharmacol Exp Ther.* 365(3):519-525.
- Marsousi N, Doffey-Lazeyras F, Rudaz S, Desmeules JA, Daali Y. 2016. Intestinal permeability and P-glycoprotein-mediated efflux transport of ticagrelor in Caco-2 monolayer cells. *Fundam Clin Pharmacol.* 30(6):577-584.
- Martin P, Gillen M, Millson D, Oliver S, Brealey C, Elsby R, Baluom M, Lau D, Mant T. 2015. Effects of fostamatinib on the pharmacokinetics of digoxin (a P-glycoprotein substrate): Results from in vitro and phase I clinical studies. *Clin Ther.* 37(12):2811-2822.
- Martinec O, Huliciak M, Staud F, Cecka F, Vokral I, Cervený L. 2019. Anti-HIV and anti-hepatitis C virus drugs inhibit P-glycoprotein efflux activity in Caco-2 cells and precision-cut rat and human intestinal slices. *Antimicrob Agents Chemother.* 63(11):e00910-19.
- Mason CW, Hassan HE, Kim KP, Cao J, Eddington ND, Newman AH, Voulalas PJ. 2010. Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D<sub>3</sub> receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. *J Pharmacol Exp Ther.* 333(3):854-864.
- Matsumoto T, Kaifuchi N, Mizuhara Y, Warabi E, Watanabe J. 2018. Use of a Caco-2 permeability assay to evaluate the effects of several Kampo medicines on the drug transporter P-glycoprotein. *J Nat Med.* 72(4):897-904.
- Mease K, Sane R, Podila L, Taub ME. 2012. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: A strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. *J Pharm Sci.* 101(5):1888-1897.
- Mensch J, Melis A, Mackie C, Verreck G, Brewster ME, Augustijns P. 2010. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. *Eur J Pharm Biopharm.* 74(3):495-502.
- Metre S, Mukesh S, Samal SK, Chand M, Sangamwar AT. 2018. Enhanced biopharmaceutical performance of rivaroxaban through polymeric amorphous solid dispersion. *Mol Pharm.* 15(2):652-668.
- Meyer MR, Wagmann L, Schneider-Daum N, Loretz B, de Souza Carvalho C, Lehr CM, Maurer HH. 2015. P-glycoprotein interactions of novel psychoactive substances - stimulation of ATP consumption and transport across Caco-2 monolayers. *Biochem Pharmacol.* 94(3):220-226.

- Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, Okudaira N, Izumi T. 2014. Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. *Drug Metab Dispos.* 42(4):520-528.
- Miliotis T, Ali L, Palm JE, Lundqvist AJ, Ahnoff M, Andersson TB, Hilgendorf C. 2011. Development of a highly sensitive method using liquid chromatography-multiple reaction monitoring to quantify membrane P-glycoprotein in biological matrices and relationship to transport function. *Drug Metab Dispos.* 39(12):2440-2449.
- Min JS, Kim D, Park JB, Heo H, Bae SH, Seo JH, Oh E, Bae SK. 2016. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans. *Drug Des Devel Ther.* 10:2959-2972.
- Ming X, Knight BM, Thakker DR. 2011. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. *Mol Pharm.* 8(5):1677-1686.
- Mitra P, Audus K, Williams G, Yazdani M, Galinis D. 2011. A comprehensive study demonstrating that P-glycoprotein function is directly affected by changes in pH: Implications for intestinal pH and effects on drug absorption. *J Pharm Sci.* 100(10):4258-4262.
- Mitra P, Venitz J, Yuan Y, Zhang Y, Gerk PM. 2011. Preclinical disposition (in vitro) of novel  $\mu$ -opioid receptor selective antagonists. *Drug Metab Dispos.* 39(9):1589-1596.
- Miyake M, Nakai D. 2017. Effect of proinflammatory cytokine IL-6 on efflux transport of rebamipide in Caco-2 cells. *Xenobiotica.* 47(9):821-824.
- Miyamoto R, Nozawa T, Shiozuka K, Tabata K. 2019. The impact of endogenous breast cancer resistance protein on human P-glycoprotein-mediated transport assays using LLC-PK1 cells transfected with human P-glycoprotein. *J Pharm Sci.* 108(3):1085-1089.
- Mmopele K, Combrinck S, Hamman J, Willers C, Chen W, Viljoen A. 2018. potential herb-drug pharmacokinetic interactions between African wild olive leaf extract and selected antihypertensive drugs. *Planta Med.* 84(12-13):886-894.
- Mo R, Xiao Y, Sun M, Zhang C, Ping Q. 2011. Enhancing effect of N-octyl-O-sulfate chitosan on etoposide absorption. *Int J Pharm.* 409(1-2):38-45.
- Moaddel R, Hamid R, Patel S, Bullock PL, Wainer IW. 2006. Identification of P-glycoprotein substrates using open tubular chromatography on an immobilized P-glycoprotein column: Comparison of chromatographic results with Caco-2 permeability. *Anal Chim Acta.* 578(1):25-30.
- Moss DM, Kwan WS, Liptrott NJ, Smith DL, Siccardi M, Khoo SH, Back DJ, Owen A. 2011. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. *Antimicrob Agents Chemother.* 55(2):879-887.
- Mouly SJ, Paine MF, Watkins PB. 2004. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. *J Pharmacol Exp Ther.* 308(3):941-948.
- Mukkavilli R, Jadhav G, Vangala S. 2017. Evaluation of drug transport in MDCKII-wild type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 cell lines. *Curr Pharm Biotechnol.* 18(14):1151-1158.
- Nakamaru Y, Hayashi Y, Sekine M, Kinoshita S, Thompson J, Kawaguchi A, Davies M, Jürgen Heuer H, Yamazaki H, Akimoto K. 2014. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. *Clin Ther.* 36(5):760-769.
- Nakazono Y, Arakawa H, Nishino M, Yamaki I, Oba T, Tomotoshi K, Kakinuma C, Ogihara T, Tamai I. 2021. Drug transcellular transport assay using a high porosity honeycomb film. *Biol*

Pharm Bull. 44(5):635-641.

- Neuhoff S, Artursson P, Zamora I, Ungell AL. 2006. Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells. *Pharm Res.* 23(2):350-359.
- Neuhoff S, Ungell AL, Zamora I, Artursson P. 2003. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. *Pharm Res.* 20(8):1141-1148.
- Nicolaï J, Chapy H, Gillent E, Saunders K, Ungell AL, Nicolas JM, Chanteux H. 2020. Impact of *in vitro* passive permeability in a P-gp-transfected LLC-PK1 model on the prediction of the rat and human unbound brain-to-plasma concentration ratio. *Pharm Res.* 37(9):175.
- Nožinić D, Milić A, Mikac L, Ralić J, Padovan J, Antolović R. 2010. Assessment of macrolide transport using PAMPA, Caco-2 and MDCKII-hMDR1 assays. *Croatica Chem Acta.* 83(3): 323-331.
- Obradovic T, Dobson GG, Shingaki T, Kungu T, Hidalgo IJ. 2007. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. *Pharm Res.* 24(2):318-327.
- Oda K, Nemoto H, Nagasaka Y, Kawamura A, Usui T. 2014. *In vitro* experimental system for evaluating inhibitory effect of investigational drugs on P-glycoprotein-mediated transcellular transport of tacrolimus (FK506). *Biopharm Drug Dispos.* 35(3):135-144.
- Ofer M, Wolfram S, Koggel A, Spahn-Langguth H, Langguth P. 2005. Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT? *Eur J Pharm Sci.* 25(2-3):263-271.
- Oga EF, Sekine S, Shitara Y, Horie T. 2012. P-glycoprotein mediated efflux in Caco-2 cell monolayers: the influence of herbals on digoxin transport. *J Ethnopharmacol.* 144(3):612-617.
- Oga EF, Sekine S, Shitara Y, Horie T. 2012. Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells. *Am J Trop Med Hyg.* 87(1):64-69.
- Ogihara T, Kamiya M, Ozawa M, Fujita T, Yamamoto A, Yamashita S, Ohnishi S, Isomura Y. 2006. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine. *Drug Metab Pharmacokinet.* 21(3):238-244.
- Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I. 2006. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. *Drug Metab Dispos.* 34(5):793-799.
- Ohshima M, Kamei S, Fushimi H, Mima S, Yamada T, Yamamoto T. 2019. Prediction of drug permeability using in vitro blood-brain barrier models with human induced pluripotent stem cell-derived brain microvascular endothelial cells. *Biores Open Access.* 8(1):200-209.
- Ohura K, Nakada Y, Kotani S, Imai T. 2015. Design of fexofenadine prodrugs based on tissue-specific esterase activity and their dissimilar recognition by P-glycoprotein. *J Pharm Sci.* 104(9):3076-3083.
- Ohura K, Sakamoto H, Ninomiya S, Imai T. 2010. Development of a novel system for estimating human intestinal absorption using Caco-2 cells in the absence of esterase activity. *Drug Metab Dispos.* 38(2):323-331.
- Ollier E, Hodin S, Basset T, Accassat S, Bertoletti L, Mismetti P, Delavenne X. 2015. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. *Fundam Clin Pharmacol.* 29(6):604-614.
- Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, Schellens JH. 2007. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. *Cancer Chemother Pharmacol.* 59(6):855-860.

- Ozgür B, Saaby L, Langthaler K, Brodin B. 2018. Characterization of the IPEC-J2 MDR1 (iP-gp) cell line as a tool for identification of P-gp substrates. *Eur J Pharm Sci.* 112:112-121.
- Pachot JJ, Botham RP, Haegele KD, Hwang K. 2003. Experimental estimation of the role of P-glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. *J Pharm Pharm Sci.* 6(1):1-12.
- Pade V, Stavchansky S. 1998. Link between drug absorption solubility and permeability measurements in Caco-2 cells. *J Pharm Sci.* 87(12):1604-1607.
- Palm K, Luthman K, Ros J, Grasjo J, Artursson P. 1999. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. *J Pharmacol Exp Ther.* 291(2):435-43.
- Palmgrén JJ, Mönkkönen J, Jukkola E, Niva S, Auriola S. 2004. Characterization of Caco-2 cell monolayer drug transport properties by cassette dosing using UV/fluorescence HPLC. *Eur J Pharm Biopharm.* 57(2):319-328.
- Pan G, Li T, Zeng Q, Wang X, Zhu Y. 2016. Alisol F 24 acetate enhances chemosensitivity and apoptosis of MCF-7/DOX cells by inhibiting P-glycoprotein-mediated drug efflux. *Molecules.* 21(2). pii: E183.
- Pan L, Hu H, Wang X, Yu L, Jiang H, Chen J, Lou Y, Zeng S. 2015. Inhibitory effects of neochamaejasmin B on P-glycoprotein in MDCK-hMDR1 cells and molecular docking of NCB binding in P-glycoprotein. *Molecules.* 20(2):2931-2948.
- Patel J, Hussain A, Pal D, Mitra AK. 2004. A mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells. *Am J Ther.* 11(2):114-123.
- Patel M, Mandava NK, Pal D, Mitra AK. 2014. Amino acid prodrug of quinidine: an approach to circumvent P-glycoprotein mediated cellular efflux. *Int J Pharm.* 464(1-2):196-204.
- Patel J, Buddha B, Dey S, Pal D, Mitra AK. 2004. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. *Am J Ther.* 11(4):262-277.
- Patil AG, D'Souza R, Dixit N, Damre A. 2011. Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer. *Eur J Drug Metab Pharmacokinet.* 36(3):115-119.
- Patil AG, Reddy D, D'Souza R, Damre A. 2010. Development and validation of RP-HPLC-fluorescence method for quantitative determination of quinidine, a probe substrate for P-glycoprotein inhibition assay using Caco-2 cell monolayer. *Biomed Chromatogr.* 24(6):620-625.
- Pauli-Magnus C, von Richter O, Burk O, Zielger A, Mettang T, Eichelbaum M, Fromm MF. 2000. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. *J Pharmacol Exp Ther.* 293(2):376-383.
- Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, Schinkel AH. 2005. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. *J Pharmacol Exp Ther.* 312(1):144-152.
- Peng R, Zhang H, Zhang Y, Wei DY. 2016. Impacts of *ABCB1* (G1199A) polymorphism on resistance, uptake, and efflux to steroid drugs. *Xenobiotica.* 46(10):948-952.
- Perloff MD, von Moltke LL, Greenblatt DJ. 2002. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. *J Clin Pharmacol.* 42(11):1269-1274.

- Petri N, Tannergren C, Rungstad D, Lennernäs H. 2004. Transport characteristics of fexofenadine in the Caco-2 cell model. *Pharm Res.* 21(8):1398-1404.
- Poirier A, Cascais AC, Bader U, Portmann R, Brun ME, Walter I, Hillebrecht A, Ullah M, Funk C. 2014. Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo. *Drug Metab Dispos.* 42(9):1411-1422.
- Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, Serabjit-Singh CJ. 2003. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec®), a second-generation non-sedating antihistamine. *J Pharm Sci.* 92(10):2082-2089.
- Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. *Pharm Res.* 16(8):1206-1212.
- Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. *J Pharmacol Exp Ther.* 299(2):620-628.
- Profit L, Eagling VA, Back DJ. 1999. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. *AIDS.* 13(13):1623-1627.
- Qin XL, Bi HC, Wang XD, Li JL, Wang Y, Xue XP, Chen X, Wang CX, Xu J, Wang YT, Huang M. 2010. Mechanistic understanding of the different effects of Wuzhi tablet (*Schisandra sphenanthera* extract) on the absorption and first-pass intestinal and hepatic metabolism of tacrolimus (FK506). *Int J Pharm.* 389(1-2):114-121.
- Raaphorst RM, Savolainen H, Cantore M, van de Steeg E, van Waarde A, Colabufo NA, Elsinga PH, Lammertsma AA, Windhorst AD, Luurtsema G. 2017. Comparison of in vitro assays in selecting radiotracers for in vivo P-glycoprotein PET imaging. *Pharmaceuticals.* 10(3):pii:E76.
- Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. 2006. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. *Drug Metab Dispos.* 34(5):786-792.
- Ravikumar Reddy D, Khurana A, Bale S, Ravirala R, Samba Siva Reddy V, Mohankumar M, Godugu C. 2016. Natural flavonoids silymarin and quercetin improve the brain distribution of co-administered P-gp substrate drugs. *Springerplus.* 5(1):1618.
- Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, Rhodes GR. 2006. Mechanism of active renal tubular efflux of tenofovir. *Antimicrob Agents Chemother.* 50(10):3297-3304.
- Reese MJ, Bowers GD, Humphreys JE, Gould EP, Ford SL, Webster LO, Polli JW. 2016. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from *in vitro* studies and a clinical investigation with midazolam. *Xenobiotica.* 46(5):445-456.
- Rege BD, Yu LX, Hussain AS, Polli JE. 2001. Effect of common excipients on Caco-2 transport of low-permeability drugs. *J Pharm Sci.* 90(11):1776-86.
- Reyner EL, Sevidal S, West MA, Clouser-Roche A, Freiwald S, Fenner K, Ullah M, Lee CA, Smith BJ. 2013. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. *Drug Metab Dispos.* 41(8):1575-1583.
- Rodriguez-Proteau R, Mata JE, Miranda CL, Fan Y, Brown JJ, Buhler DR. 2006. Plant

- polyphenols and multidrug resistance: Effects of dietary flavonoids on drug transporters in Caco-2 and MDCKII-MDR1 cell transport models. *Xenobiotica*. 36(1):41-58.
- Rossi Sebastiano M, Doak BC, Backlund M, Poongavanam V, Over B, Ermondi G, Caron G, Matsson P, Kihlberg J. 2018. Impact of dynamically exposed polarity on permeability and solubility of chameleonic drugs beyond the rule of 5. *J Med Chem*. 61(9):4189-4202.
- Rouquayrol M, Gaucher B, Roche D, Greiner J, Vierling P. 2002. Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers. *Pharm Res*. 19(11):1704-1712.
- Saaby L, Tfelt-Hansen P, Brodin B. 2015. The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1. *Pharmacol Res Perspect*. 3(4):e00151
- Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM. 2007. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. *J Pharm Pharm Sci*. 10(3):319-331.
- Saito H, Fukasawa Y, Otsubo Y, Yamada K, Sezaki H, Yamashita S. 2000. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers. *Pharm Res*. 17(6):761-765.
- Salama NN, Yang Z, Bui T, Ho RJ. 2006. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. *J Pharm Sci*. 95(10):2293-2308.
- Sampson KE, Brinker A, Pratt J, Venkatraman N, Xiao Y, Blasberg J, Steiner T, Bournier M, Thompson DC. 2015. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells. *Drug Metab Dispos*. 43(2):199-207.
- Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, Liu R, Anderson MS, Behm MO, Fan L, *et al*. 2019. Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. *Xenobiotica*. 49(4):422-432.
- Sandage B, Sabounjian L, Shipley J, Profy A, Lasseter K, Fox L, Harnett M. 2006. Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. *J Clin Pharmacol*. 46(7):776-784.
- Sato S, Tohyama K, Kosugi Y. 2020. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using *in vitro* efflux activities. *Eur J Pharm Sci*. 142:105119.
- Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J. 2003. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. *J Med Chem*. 46(9):1716-1725.
- Senarathna SM, Page-Sharp M, Crowe A. 2016. The interactions of P-glycoprotein with antimalarial drugs, including substrate affinity, inhibition and regulation. *PLoS One*. 11(4):e0152677.
- Senarathna SM, Crowe A. 2015. The influence of passage number for Caco2 cell models when evaluating P-gp mediated drug transport. *Pharmazie*. 70(12):798-803.
- Sevin E, Dehouck L, Fabulas-da Costa A, Cecchelli R, Dehouck MP, Lundquist S, Culot M. 2013. Accelerated Caco-2 cell permeability model for drug discovery. *J Pharmacol Toxicol*



Methods. 68(3):334-339.

- Shah D, Paruchury S, Matta M, Chowan G, Subramanian M, Saxena A, Soars MG, Herbst J, Haskell R, Marathe P, Mandlekar S. 2014. A systematic evaluation of solubility enhancing excipients to enable the generation of permeability data for poorly soluble compounds in Caco-2 model. *Drug Metab Lett.* 8(2):109-118.
- Shaik AN, Bohnert T, Williams DA, Gan LL, LeDuc BW. 2016. Mechanism of drug-drug interactions between warfarin and statins. *J Pharm Sci.* 105(6):1976-1986.
- Shebley M, Liu J, Kavetskaia O, Sydor J, de Morais SM, Fischer V, Nijsen MJMA, Bow DAJ. 2017. Mechanisms and predictions of drug-drug interactions of the hepatitis C virus three direct-acting antiviral regimen: Paritaprevir/ritonavir, ombitasvir, and dasabuvir. *Drug Metab Dispos.* 45(7):755-764.
- Shen H, Yao M, Sinz M, Marathe P, Rodrigues AD, Zhu M. 2019. Renal excretion of dabigatran: The potential role of multidrug and toxin extrusion (MATE) proteins. *Mol Pharm.* 16(9):4065-4076.
- Shen H, Lee FY, Gan J. 2011. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). *J Pharmacol Exp Ther.* 337(2):423-432.
- Shen S, He Y, Zeng S. 2007. Stereoselective regulation of MDR1 expression in Caco-2 cells by cetirizine enantiomers. *Chirality.* 19(6):485-490.
- Shi J, Cao B, Zha WB, Wu XL, Liu LS, Xiao WJ, Gu RR, Sun RB, Yu XY, Zheng T, *et al.* 2013. Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo. *Acta Pharmacol Sin.* 34(10):1349-58.
- Shibata N, Inoue Y, Fukumoto K, Nishimura A, Fukushima K, Yoshikawa Y, Spiteller G, Takada K. 2004. Evaluation of factors to decrease bioavailability of cyclosporin A in rats with gentamicin-induced acute renal failure. *Biol Pharm Bull.* 27(3):384-391.
- Shin E, Shin N, Oh JH, Lee YJ. 2017. High-dose metformin may increase the concentration of atorvastatin in the liver by inhibition of multidrug resistance-associated protein 2. *J Pharm Sci.* 106(4):961-967.
- Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I. 2010. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. *J Pharmacol Exp Ther.* 332(1):181-189.
- Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, Langguth P, Tamai I. 2009. Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). *Pharm Res.* 26(3):560-567
- Shirasaka Y, Kawasaki M, Sakane T, Omatsu H, Moriya Y, Nakamura T, Sakaeda T, Okumura K, Langguth P, Yamashita S. 2006. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport. *Drug Metab Pharmacokinet.* 21(5):414-423.
- Sigafoos JF, Bowers GD, Castellino S, Culp AG, Wagner DS, Reese MJ, Humphreys JE, Hussey EK, O'Connor Semmes RL, Kapur A, *et al.* 2012. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. *Drug Metab Dispos.* 40(11):2090-2101.
- Sikri V, Pal D, Jain R, Kalyani D, Mitra AK. 2004. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux. *Am J Ther.* 11(6):433-442.

- Singh R, Rachumallu R, Bhateria M, Panduri J, Bhatta RS. 2015. *In vitro* effects of standardized extract of *Bacopa monniera* and its five individual active constituents on human P-glycoprotein activity. *Xenobiotica*. 45(8):741-749.
- Siissalo S, Laitinen L, Koljonen M, Vellonen KS, Kortejärvi H, Urtti A, Hirvonen J, Kaukonen AM. 2007. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. *Eur J Pharm Biopharm*. 67(2):548-554.
- Skolnik S, Lin X, Wang J, Chen XH, He T, Zhang B. 2010. Towards prediction of *in vivo* intestinal absorption using a 96-well Caco-2 assay. *J Pharm Sci*. 99(7):3246-3265.
- Smalley J, Marino AM, Xin B, Olah T, Balimane PV. 2007. Development of a quantitative LC-MS/MS analytical method coupled with turbulent flow chromatography for digoxin for the *in vitro* P-gp inhibition assay. *J Chromatogr B Analyt Technol Biomed Life Sci*. 854(1-2):260-267.
- Soldner A, Christians U, Susanto M, Wachter VJ, Silverman JA, Benet LZ. 1999. Grapefruit juice activates P-glycoprotein-mediated drug transport. *Pharm Res*. 16(4):478-485.
- Spahn-Langguth H, Langguth P. 2001. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. *Eur J Pharm Sci*. 12(4):361-367.
- Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G. 2001. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. *J Pharmacol Exp Ther*. 296(2):584-591.
- Störmer E, von Moltke LL, Perloff MD, Greenblatt DJ. 2002. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. *Pharm Res*. 19(7):1038-1045.
- Störmer E, Perloff MD, von Moltke LL, Greenblatt DJ. 2001. Methadone inhibits rhodamine123 transport in Caco-2 cells. *Drug Metab Dispos*. 29(7):954-956.
- Sugihara N, Toyama K, Michihara A, Akasaki K, Tsuji H, Furuno K. 2006. Effect of benzo[a]pyrene on P-glycoprotein-mediated transport in Caco-2 cell monolayer. *Toxicology*. 223(1-2):156-165.
- Sumsakul W, Na-Bangchang K. 2016. Permeability of plumbagin across human intestinal cell in vitro. *Arch Pharm Res*. 39(3):380-389.
- Sun S, Chen Z, Li L, Sun D, Tian Y, Pan H, Bi H, Huang M, Zeng S, Jiang H. 2012. The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP. *Xenobiotica*. 42(12):1197-1205.
- Sundby E, Han J, Kaspersen SJ, Hoff BH. 2015. *In vitro* baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib. *Eur J Pharm Sci*. 80:56-65.
- Susanto M, Benet LZ. 2002. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? *Pharm Res*. 19(4):457-462.
- Sziráki I, Erdo F, Beéry E, Molnár PM, Fazakas C, Wilhelm I, Makai I, Kis E, Herédi-Szabó K, Abonyi T, *et al*. 2011. Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an *in vitro* *in vivo* correlation study. *J Biomol Screen*. 16(8):886-894.
- Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P. 2004. Exploring the quantitative relationship between the level of *MDR1* transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. *Eur J Pharm Sci*. 21(1):69-75.
- Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K. 2002. Interaction of digoxin with antihypertensive drugs *via* MDR1. *Life Sci*. 70(13):1491-1500.
- Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa SI, Ebihara T, Katoh M, Yokoi T, Asahi

- S. 2006. Establishment and characterization of the transformants stably-expressing *MDR1* derived from various animal species in LLC-PK<sub>1</sub>. *Pharm Res.* 23(7):1460-1472.
- Tang F, Ouyang H, Yang JZ, Borchardt RT. 2004. Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers. *J Pharm Sci.* 93(5):1185-1194.
- Tang F, Horie K, Borchardt RT. 2002. Are MDCK cells transfected with the human *MDR1* gene a good model of the human intestinal mucosa? *Pharm Res.* 19(6):765-772.
- Tang F, Horie K, Borchardt RT. 2002. Are MDCK cells transfected with the human *MRP2* gene a good model of the human intestinal mucosa? *Pharm Res.* 19(6):773-779.
- Tanino T, Nawa A, Kondo E, Kikkawa F, Daikoku T, Tsurumi T, Luo C, Nishiyama Y, Takayanagi Y, Nishimori K, *et al.* 2007. Paclitaxel-2'-ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity. *Pharm Res.* 24(3):555-565.
- Taub ME, Podila L, Ely D, Almeida I. 2005. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. *Drug Metab Dispos.* 33(11):1679-1687.
- Tarirai C, Viljoen AM, Hamman JH. 2012. Effects of dietary fruits, vegetables and a herbal tea on the *in vitro* transport of cimetidine: comparing the Caco-2 model with porcine jejunum tissue. *Pharm Biol.* 50(2):254-263.
- Taur JS, DesJardins CS, Schuck EL, Wong YN. 2011. Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 *abcb1a*-deficient mice and Caco-2 cells. *Xenobiotica.* 41(4):320-326.
- Taur JS, Rodriguez-Proteau R. 2008. Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. *Xenobiotica.* 38(12):1536-50.
- Templeton I, Ravenstijn P, Sensenhauser C, Snoeys J. 2016. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. *Biopharm Drug Dispos.* 37(1):15-27.
- Teow HM, Zhou Z, Najlah M, Yusof SR, Abbott NJ, D'Emanuele A. 2013. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. *Int J Pharm.* 441(1-2):701-711.
- Thiel-Demby VE, Humphreys JE, St. John Williams LA, Ellens HA, Shah N, Ayrton AD, Polli JW. 2009. Biopharmaceutics classification system: Validation and learnings of an *in vitro* permeability assay. *Mol Pharm.* 6(1):11-18.
- Thomas J, Wang L, Clark RE, Pirmohamed M. 2004. Active transport of imatinib into and out of cells: implications for drug resistance. *Blood.* 104(12):3739-3745.
- Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Declèves X. 2010. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). *Int J Neuropsychopharmacol.* 13(7):905-915.
- Trapa PE, Troutman MD, Lau TY, Wager TT, Maurer TS, Patel NC, West MA, Umland JP, Carlo AA, Feng B, Liras JL. 2019. *In vitro-in vivo* extrapolation of key transporter activity at the blood-brain barrier. *Drug Metab Dispos.* 47(4):405-411.
- Tronde A, Nordén B, Marchner H, Wendel AK, Lennernäs H, Bengtsson UH. 2003. Pulmonary absorption rate and bioavailability of drugs *in vivo* in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. *J Pharm Sci.* 92(6):1216-1233.
- Troutman MD, Thakker DR. 2003. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory

- transport across Caco-2 cell monolayers. *Pharm Res.* 20(8):1200-1209.
- Troutman MD, Thakker DR. 2003. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. *Pharm Res.* 20(8):1210-1224.
- Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB. 2008. Breast cancer resistance protein (*ABCG2*) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an *in vivo* probe. *Pharmacogenet Genomics.* 18(5):439-448.
- Vadlapatla RK, Vadlapudi AD, Kwatra D, Pal D, Mitra AK. 2011. Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. *Int J Pharm.* 420(1):26-33.
- Vallianatou T, Strittmatter N, Nilsson A, Shariatgorji M, Hamm G, Pereira M, Källback P, Svenningsson P, Karlgren M, Goodwin RJA, Andrén PE. 2018. A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability. *Neuroimage.* 172:808-816.
- van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, Breimer DD. 2001. Assessment of active transport of HIV protease inhibitors in various cell lines and the *in vitro* blood--brain barrier. *AIDS.* 15(4):483-491.
- Venkatakrishnan K, Tseng E, Nelson FR, Rollema H, French JL, Kaplan IV, Horner WE, Gibbs MA. 2007. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. *Drug Metab Dispos.* 35(8):1341-1349.
- Versantvoort CH, Ondrewater RC, Duizer E, Van de Sandt JJ, Gilde AJ, Groten JP. 2002. Monolayers of IEC-18 cells as an *in vitro* model for screening the passive transcellular and paracellular transport across the intestinal barrier: comparison of active and passive transport with the human colon carcinoma Caco-2 cell line. *Environ Toxicol Pharmacol.* 11(3-4):335-344.
- Verscheijden LFM, Litjens CHC, Koenderink JB, Mathijssen RHJ, Verbeek MM, de Wildt SN, Russel FGM. 2021. Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children. *PLoS Comput Biol.* 17(3):e1008786.
- Veszélka S, Tóth A, Walter FR, Tóth AE, Gróf I, Mészáros M, Bocsik A, Hellinger É, Vastag M, Rákhely G, Deli MA. 2018. Comparison of a rat primary cell-based blood-brain barrier model with epithelial and brain endothelial cell lines: Gene expression and drug transport. *Front Mol Neurosci.* 11:166.
- Volpe DA, Hamed SS, Zhang LK. 2014. Use of different parameters and equations for calculation of IC<sub>50</sub> values in efflux assays: potential sources of variability in IC<sub>50</sub> determination. *AAPS J.* 16(1):172-180.
- Volpe DA, Faustino PJ, Ciavarella AB, Asafu-Adjaye EB, Ellison CD, Yu LX, Hussain AS. 2007. Classification of drug permeability with a Caco-2 cell monolayer assay. *Clin Res Reg Affairs.* 24(1):39-47.
- Volpe DA. 2004. Permeability classification of representative fluoroquinolones by a cell culture method. *AAPS PharmSci.* 6(2):1-6.
- Walle UK, Walle T. 1998. Taxol transport by human intestinal epithelial Caco-2 cells. *Drug Metab Dispos.* 26(4):343-346.
- Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A, Hidalgo IJ. 2008. Application and limitation of inhibitors in drug-transporter interactions studies. *Int J Pharm.* 356(1-2):12-18.

- Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, Hidalgo IJ. 2005. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. *Int J Pharm.* 288(2):349-359.
- Wang R, Sun X, Deng YS, Qiu XW. 2019. Effects of MDR1 1236C > T-2677G > T-3435C > T polymorphisms on the intracellular accumulation of tacrolimus, cyclosporine A, sirolimus and everolimus. *Xenobiotica.* 49(11):1373-1378.
- Wang T, Sun Y, Ma W, Yang Z, Yang J, Liu J, Fan H, Yang Y, Gu J, Fawcett JP, Guo Y. 2015. Trantinterol, a novel  $\beta$ 2-adrenoceptor agonist, noncompetitively inhibits P-glycoprotein function in vitro and in vivo. *Mol Pharm.* 12(1):1-9.
- Wang X, Zhang X, Huang X, Li Y, Wu M, Liu J. 2016. The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4. *Xenobiotica.* 46(7):651-658.
- Wang Z, Pal D, Mitra AK. 2012. Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir. *J Pharm Sci.* 101(9):3199-3213.
- Watanabe N, Higashi H, Nakamura S, Nomura K, Adachi Y, Taguchi M. 2018. The possible clinical impact of risperidone on P-glycoprotein-mediated transport of tacrolimus: A case report and in vitro study. *Biopharm Drug Dispos.* 39(1):30-37.
- Wegler C, Gazit M, Issa K, Subramaniam S, Artursson P, Karlgren M. 2021. Expanding the efflux in vitro assay toolbox: A CRISPR-Cas9 edited MDCK cell line with human BCRP and completely lacking canine MDR1. *J Pharm Sci.* 110(1):388-396.
- Weinheimer M, Fricker G, Burhenne J, Mylius P, Schubert R. 2017. The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison. *Eur J Pharm Sci.* 108:13-22.
- Wempe MF, Wright C, Little JL, Lightner JW, Large SE, Caflisch GB, Buchanan CM, Rice PJ, Wachter VJ, Ruble KM, Edgar KJ. 2009. Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS. *Int J Pharm.* 370(1-2):93-102.
- Williams GC, Knipp GT, Sinko PJ. 2003. The effect of cell culture conditions on saquinavir transport through, and interactions with, MDCKII cells overexpressing hMDR1. *J Pharm Sci.* 92(10):1957-1967.
- Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D. 1994. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. *Biochem Pharmacol.* 48(7):1528-1530.
- Woo JS, Lee CH, Shim CK, Hwang SJ. 2003. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. *Pharm Res.* 20(1):24-30.
- Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ. 2009. *MDR1 (ABCB1)* G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. *Cancer Chemother Pharmacol.* 64(1):183-188.
- Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. 2005. *MDR1* G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. *AIDS.* 19(15):1617-1625.
- Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. 2004. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. *J Pharmacol Exp Ther.* 310(3):1199-1207.
- Wright JA, Haslam IS, Coleman T, Simmons NL. 2011. Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers. *Eur J Pharmacol.* 672(1-3):70-76.

- Wu X, Whitfield LR, Stewart BH. 2000. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. *Pharm Res.* 17(2):209-215.
- Xia CQ, Liu N, Yang D, Miwa G, Gan LS. 2005. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. *Drug Metab Dispos.* 33(5):637-643.
- Xin HW, Schwab M, Klotz U. 2006. Transport studies with 5-aminosalicylate. *Eur J Clin Pharmacol.* 62(10):871-875.
- Xu J, Go ML, Lim LY. 2003. Modulation of digoxin transport across Caco-2 cell monolayers by citrus fruit juices: lime, lemon, grapefruit, and pummelo. *Pharm Res.* 20(2):169-176.
- Yang LQ, Wang B, Gan H, Fu ST, Zhu XX, Wu ZN, Zhan DW, Gu RL, Dou GF, Meng ZY. 2012. Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 *in vivo*. *Biopharm Drug Dispos.* 33(8):425-436.
- Yang XX, Hu ZP, Xu AL, Duan W, Zhu YZ, Huang M, Sheu FS, Zhang Q, Bian JS, Chan E, *et al.* 2006. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor- $\alpha$  inhibitor. *J Pharmacol Exp Ther.* 319(1):82-104.
- Yano K, Shimizu S, Tomono T, Ogihara T. 2017. Gastrointestinal hormone cholecystikinin increases P-glycoprotein membrane localization and transport activity in Caco-2 cells. *J Pharm Sci.* 106(9):2650-2656.
- Yasar U, Annas A, Svensson JO, Lazorova L, Artursson P, Al-Shurbaji A. 2005. Ketobemidone is a substrate for cytochrome P450C9 and 3A4, but not for P-glycoprotein. *Xenobiotica.* 35(8):785-796.
- Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW. 2003. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. *Pharm Res.* 20(11):1794-1803.
- Yazdanian, M., Briggs, K., Jankovsky, C. Hawi A. 2004. The “high solubility” definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. *Pharm Res.* 21(2):293-299.
- Ye D, Harder A, Fang Z, Weinheimer M, Laplanche L, Mezler M. 2020. Characterization and validation of canine P-glycoprotein-deficient MDCK II cell lines for efflux substrate screening. *Pharm Res.* 37(10):194.
- Ye RP, Chen ZD. 2017. Saikosaponin A, an active glycoside from *Radix bupleuri*, reverses P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cells and HepG2/ADM cells. *Xenobiotica.* 47(2):176-184.
- Yee S. 1997. *In vitro* permeability across Caco-2 cells (colonic) can predict *in vivo* (small intestinal) absorption in man - fact or myth. *Pharm Res.* 14(6):763-766.
- Yoo HH, Lee M, Chung HJ, Lee SK, Kim DH. 2007. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. *J Agric Food Chem.* 55(18):7620-7625.
- Yoo HH, Lee M, Lee MW, Lim SY, Shin J, Kim DH. 2007. Effects of *Schisandra lignans* on P-glycoprotein-mediated drug efflux in human intestinal Caco-2. *Planta Med.* 73(5):444-450.
- Yoshida N, Takagi A, Kitazawa H, Kawakami J, Adachi I. 2006. Effects of citronellal, a monoterpenoid in *Zanthoxyli Fructus*, on the intestinal absorption of digoxin *in vitro* and *in vivo*. *J Pharm Sci.* 95(3):552-560.
- Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R, Coffin M. 1999. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and

- permeability. *Pharm Res.* 16(12):1812-1817.
- Yuan H, Lu LJ, Du YZ, Hu FQ. 2011. Stearic acid-g-chitosan polymeric micelle for oral drug delivery: in vitro transport and in vivo absorption. *Mol Pharm.* 8(1):225-238.
- Yue GG, Cheng SW, Yu H, Xu ZS, Lee JK, Hon PM, Lee MY, Kennelly EJ, Deng G, Yeung SK, *et al.* 2012. The role of turmerones on curcumin transportation and P-glycoprotein activities in intestinal Caco-2 cells. *J Med Food.* 15(3):242-252.
- Zhang J, Zhou F, Wu X, Gu Y, Ai H, Zheng Y, Li Y, Zhang X, Hao G, Sun J, *et al.* 2010. 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions. *Drug Metab Dispos.* 38(12):2179-2187.
- Zhang S, Morris ME. 2003. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. *Pharm Res.* 20(8):1184-1191.
- Zhang W, Lim LY. 2008. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. *Drug Metab Dispos.* 36(7):1283-1290.
- Zhao Q, Wang Y, Wang H, Feng L. 2018. Effects of glycyrrhizin on the pharmacokinetics of puerarin in rats. *Xenobiotica.* 48(11):1157-1163.
- Zheng Y, Benet LZ, Okochi H, Chen X. 2015. pH Dependent but not P-gp dependent bidirectional transport study of S-propranolol: The importance of passive diffusion. *Pharm Res.* 32(8):2516-2526.
- Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, Feng B. 2009. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl) propanoic acid (PF-407288) in mice. *Drug Metab Dispos.* 37(5):946-955.
- Zhu H, Zhu SC, Shakya S, Mao Q, Ding CH, Long MH, Li SL. 2015. Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. *J Pharm Biomed Anal.* 107:119-124.
- Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL. 2007. Risperidone and paliperidone inhibit p-glycoprotein activity *in vitro*. *Neuropsychopharmacology.* 32(4):757-764.
- Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, Gefroh HA, Devane CL. 2006. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. *J Pharmacol Exp Ther.* 317(2):850-807.